Lyra Therapeutics (LYRA) Change in Accured Expenses (2019 - 2025)

Lyra Therapeutics (LYRA) has reported Change in Accured Expenses for 7 consecutive years, with -$328000.0 the latest figure, recorded in Q4 2025.

• Change in Accured Expenses for Q4 2025 came in at -$328000.0, up 42.96% year-over-year; the trailing twelve-month figure through Dec 2025 was -$1.8 million (up 69.69% YoY), and the FY2025 annual result was -$1.8 million, up 69.69% from the prior year.
• Change in Accured Expenses for Q4 2025 stood at -$328000.0, up from -$942000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $2.3 million in Q3 2023, with the low at -$3.3 million in Q2 2024.
• A 5-year average of -$13950.0 and a median of -$144500.0 in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses soared 604.32% in 2022 and sank 2564.37% in 2023, its largest moves.
• Lyra Therapeutics' Change in Accured Expenses stood at $278000.0 in 2021, then soared by 604.32% to $2.0 million in 2022, then increased by 8.07% to $2.1 million in 2023, then slumped by 127.17% to -$575000.0 in 2024, then surged by 42.96% to -$328000.0 in 2025.
• The last three Change in Accured Expenses figures came in at -$328000.0 (Q4 2025), -$942000.0 (Q3 2025), and -$202000.0 (Q2 2025), per Business Quant data.